Treatment of Evans Syndrome in Systemic Lupus Erythematosus

Evans syndrome (ES) can present as a manifestation of systemic lupus erythematosus (SLE), a chronic autoimmune condition. Recognition of this association directly shapes the diagnostic workup and the treatment approach taken.

Clinical Scenario

Systemic lupus erythematosus is a recognised classical cause of Evans syndrome in adults. When ES is diagnosed, a systematic search for SLE — including evaluation for antinuclear antibodies — is considered a standard part of the workup. This protocol addresses first-line management of Evans syndrome specifically in the setting of confirmed SLE.

Treatment Approach

In SLE-associated Evans syndrome, the initial treatment strategy follows a corticosteroid-based first-line approach. The structured protocol outlines the full management pathway beyond this initial step.

Full regimen and evidence-based sequencing available via the protocol →

Instant Access to Structured Evidence-Based Regimens

References

Another classical cause of ES in adults is SLE and therefore, searching for the presence of positive antinuclear antibodies should be systematic at the time of ES.

For SLE or CVID-associated ES, the initial strategy is similar to the one of the primary ES, rituximab being a good corticosteroid-sparing 2nd line option while splenectomy is not recommended in those settings.

View source ↗